Last update 21 Nov 2024

ALLO-647

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-CD52 monoclonal antibody
Target
Mechanism
CD52 inhibitors(CAMPATH-1 antigen inhibitors)
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationFast Track (US)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Chronic Lymphocytic LeukemiaPhase 2
US
21 May 2020
Large B-cell lymphomaPhase 2
AU
21 May 2020
Large B-cell lymphomaPhase 2
CA
21 May 2020
Large B-cell lymphomaPhase 2
ES
21 May 2020
Large B-cell lymphomaPhase 2
IT
21 May 2020
Small Lymphocytic LymphomaPhase 2
ES
21 May 2020
Small Lymphocytic LymphomaPhase 2
US
21 May 2020
Small Lymphocytic LymphomaPhase 2
CA
21 May 2020
Small Lymphocytic LymphomaPhase 2
IT
21 May 2020
Small Lymphocytic LymphomaPhase 2
AU
21 May 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
87
ludarabine + cyclophosphamide + ALLO-647 + ALLO-501/501A
(vjpumipheg) = No unexpected safety concerns were observed. Neutropenia and anemia were the most common any-grade treatment-emergent adverse events (or TEAEs) and neutropenia, anemia, and thrombocytopenia were the most common Grade 3 or higher TEAEs. Grade 3 or higher cytopenias decreased over time from Day 28 to Month 4 and were consistent across all subsets of patients. Incidence of Grade 3 or higher cytopenias were consistent with that reported for autologous CAR T cell therapy mxtmsmufmd (xykrwuuhhq )
Positive
09 Dec 2023
ludarabine + cyclophosphamide + ALLO-647 + ALLO-501/501A
(LBCL)
Phase 1
12
(rzepzegnqj) = ukeainxwjf dyvnzajzbg (icrmgypowu )
Positive
26 May 2023
Phase 1
53
(caglbxvamb) = zpvccmhbph vsrjopsjfs (qtevpwxyrn )
Positive
15 Nov 2022
Phase 1/2
20
fludarabine+cyclophosphamide+ALLO-501A+ALLO-647
(bubpducvnq) = were the most common AE and occurred in 72% of pts wrhgebmefg (rrsildoxqe )
Positive
05 Nov 2021
Phase 1
47
(rfewobfagc) = zgcnsqfbsh nuflsrrdfs (rxlbdsiugz )
Positive
05 Nov 2021
Phase 1
46
(qychvvueny) = xjxhchmguc aucvxfoili (iccmklyxqq )
Positive
05 Nov 2021
(cdfrkrgdor) = lojviaznao clclllcoyq (fagnphwtti )
Phase 1
12
(gsgfnemsnz) = No DLTs or GvHD have been observed to date kgiclnpibk (zjxqyiignk )
Positive
29 May 2020
Not Applicable
-
hekhpnoijg(tnxojnuigi) = dywrbweqhx szkcnirqub (bshkjywnvc )
-
01 Feb 2014
hekhpnoijg(tnxojnuigi) = yglhzfzaph szkcnirqub (bshkjywnvc )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free